Videos

Jeffrey Dunn, MD, and Regina Berkovich, MD, PhD, provide an overview of the impact vaccinations and immunization may have on multiple sclerosis therapies, highlighting the ability of S1P treatments to remain effective.

Regina Berkovich, MD, PhD, provides insight on the considerations and patient awareness of the risk of infections with disease-modifying therapies in patients with multiple sclerosis.

Experts in neurology share their hopes for the future of multiple sclerosis treatment and discuss unmet needs and novel targets.

Amit Bar-Or, MD, FRCPC, and Bridget A. Bagert, MD, share their opinions on how to move investigative treatments for multiple sclerosis off the laboratory bench and into clinical practice.

Doctors in neurology comment on the hidden symptoms of multiple sclerosis and debate whether they should be treatment targets.

A migraine specialist discusses monitoring of patients with acute migraine.

Dr Okuda shares his thoughts on the importance of patient dialogue in successful management of multiple sclerosis.

Dr Williams talks about the role NP/PA play in treating patients with migraines.

A multiple sclerosis expert, Dr Darin Okuda reviews long-term outcomes with ozanimod in DAYBREAK trial based on the number of relapses that was presented at EAN 2022.

Dr Darin Okuda discusses strategies for treatment selection and management of relapses in multiple sclerosis.

Ericka Wong, MD, comments on gaps in care in myasthenia gravis and provides take-home messages for physicians treating patients with this condition.

An expert neurologist discusses zilucoplan and other pipeline agents in the treatment of myasthenia gravis.

The neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed new findings on whether initial cognitive symptoms have similar rates of functional decline across a handful of neurodegenerative disorders. [WATCH TIME: 3 minutes]

The chief medical officer and cofounder of Linus Health provided background on the reasoning for the measures used in a new machine learning algorithm that classifies cognitive status. [WATCH TIME: 3 minutes]

Dr Jacqueline Nicholas hypothesizes about the utility of neurofilaments as a biomarker of disease severity in patients with multiple sclerosis.

Heidi Crayton, MD, and Jacqueline Nicholas, MD, review the importance of long-term safety data in the management of patients with multiple sclerosis, and Flavia Nelson, MD, discusses her approach to counseling patients on the safety considerations regarding new S1P modulating agents.

The assistant director of computational biology at Stanford University discussed the knowns and unknowns of 2 rare missense variants and their associations with decreased Alzheimer disease risk. [WATCH TIME: 4 minutes]

The medical director of the Deanna and Sidney Wolk Center for Memory Health provided background on his new study using multimodal digital biomarkers to classify patients with mild cognitive impairment. [WATCH TIME: 5 minutes]

Episode 24 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Joseph R. Berger, MD, of the University of Pennsylvania. [WATCH TIME: 7 minutes]

The associate neurologist-in-chief at Boston Children’s Hospital discussed the 4-copy conundrum and whether treatment decisions differ based on SMN2 copies for patients with spinal muscular atrophy. [WATCH TIME: 2 minutes]

The assistant director of computational biology at Stanford University provided background on recent findings of two rare APOE missense variants and reduced risk of Alzheimer disease associated with them. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending July 30, 2022. [WATCH TIME: 4 minutes]

Kelly Knupp, MD, provides insight on optimizing treatment for patients with Lennox-Gastaut Syndrome.

Dr Kelly Knupp examines data on fenfluramine and cannabidiol for the management of Lennox-Gastaut Syndrome.

Dr Brownlee shares his advice and recommendations from national MS society on providing cognitive care for patients suffering from MS.

A multiple sclerosis expert, Dr Brownlee shares study design and clinical data on relapse following discontinuation of ozanimod in patients with multiple sclerosis.

Dr Wallace Brownlee discusses reasons of and clinical impact of treatment discontinuation in multiple sclerosis.

The professor of psychiatry and cell biology at NYU Langone provided insight on the reaction to a new paper that challenges how traditional drug development has approached Alzheimer disease. [WATCH TIME: 4 minutes]

Experts in neurology discuss the considerations and practicalities of treating patients with multiple sclerosis who may undergo surgery and explore the role of treatment holidays.

Regina Berkovich, MD, PhD, comments on the role of patient education in engaging ethnically diverse and underrepresented patient populations with multiple sclerosis in their treatment plans.